Paths of Progress 2023
The articles below are featured in the 2023 issue of our Paths of Progress magazine. To see the entire publication, which includes Dana-Farber's 2022 Annual Report, please download the PDF version.
Bispecific antibodies are new cancer drugs modeled after the body's own disease-fighting antibodies, but with a sort of superpower: They can bind to two different targets at one time.
How Dana-Farber is transforming the narrative in the early detection and treatment of a stubborn cancer.
Combining immunotherapy with other treatments shows great promise against certain cancers. Dana-Farber researchers are working to enhance its effectiveness, target more types of cancer, and lengthen remissions.
Five decades of scientific effort have made Dana-Farber a worldwide leader in stem cell transplants, transforming the lives of thousands of patients.
Request a Publication
Receive by mail the current issue of a Dana-Farber publication by completing this request form.
The Media Team cannot respond to patient inquiries. For more information on contacting Dana-Farber, please see Contact Us.